File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

TitlePhase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Authors
Issue Date2018
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://clincancerres.aacrjournals.org/
Citation
Clinical Cancer Research, 2018, v. 24, p. 4650-4661 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/264221
ISSN
2017 Impact Factor: 10.199
2015 SCImago Journal Rankings: 5.314
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLim, HY-
dc.contributor.authorMerle, P-
dc.contributor.authorWeiss, KH-
dc.contributor.authorYau, TCC-
dc.contributor.authorRoss, P-
dc.contributor.authorMazzaferro, V-
dc.contributor.authorBlanc, JF-
dc.contributor.authorMa, YT-
dc.contributor.authorYen, CJ-
dc.contributor.authorKocsis, J-
dc.contributor.authorChoo, SP-
dc.contributor.authorSukeepaisarnjaroen, W-
dc.contributor.authorGérolami, R-
dc.contributor.authorDufour, JF-
dc.contributor.authorGane, EJ-
dc.contributor.authorRyoo, BY-
dc.contributor.authorPeck-Radosavljevic, M-
dc.contributor.authorDao, T-
dc.contributor.authorYeo, W-
dc.contributor.authorLamlertthon, W-
dc.contributor.authorThongsawat, S-
dc.contributor.authorTeufel, M-
dc.contributor.authorRoth, K-
dc.contributor.authorReis, D-
dc.contributor.authorChilds, BH-
dc.contributor.authorKrissel, H-
dc.contributor.authorLlovet, JM-
dc.date.accessioned2018-10-22T07:51:29Z-
dc.date.available2018-10-22T07:51:29Z-
dc.date.issued2018-
dc.identifier.citationClinical Cancer Research, 2018, v. 24, p. 4650-4661-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://hdl.handle.net/10722/264221-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://clincancerres.aacrjournals.org/-
dc.relation.ispartofClinical Cancer Research-
dc.titlePhase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1078-0432.CCR-17-3588-
dc.identifier.hkuros294255-
dc.identifier.volume24-
dc.identifier.spage4650-
dc.identifier.epage4661-
dc.identifier.isiWOS:000446207700005-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats